Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
After cardiac safety signals led to a full clinical hold on Aardvark Therapeutics’ studies of ARD-101, the biotech conducted an additional safety study, in which no cardiac events were detected. Aardvark plans to resume testing the candidate next year.
Original title: “FDA uncages Aardvark’s Prader-Willi study after new data cleared safety concerns”
Amylyx shares good news for its investigational GLP-1 blocker; Definium announces positive data for its LSD-based therapy in anxiety; Summit/Akeso’s ivonescimab shows degrading survival benefits; patients treated with Neurocrine’s Prader-Willi drug experience serious adverse events; and Eli Lilly cracks down on the black market for next-gen obesity asset retatrutide.
Original title: “Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more”
Reports of seven deaths in patients who had taken Neurocrine Biosciences’ Vykat and the official termination of Aardvark Therapeutics’ Phase 3 trial after cardiac complications marked a tough day for the Prader-Willi syndrome community.
Original title: “Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug”
Rhythm Pharmaceuticals’ Imcivree reduced fat—while boosting muscle—in patients with Prader-Willi syndrome.
Original title: “Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic disease”
review of estimates of birth incidence and population prevalence over time and between countries of the rare neurodevelopmental condition prader willi syndrome
Original title: “Review of estimates of birth incidence and population prevalence over time and between countries of the rare neurodevelopmental condition Prader-Willi syndrome.”
sleeve gastrectomy in paediatric and transition age patients with prader willi syndrome a 5 year longitudinal study
Original title: “Sleeve Gastrectomy in Paediatric and Transition Age Patients with Prader-Willi Syndrome: A 5-Year Longitudinal Study.”
The company plans to unblind the late-stage study that was halted due to safety concerns, which could lead to an overhaul of its entire development program.
Original title: “FDA hold puts Aardvark Prader-Willi drug in limbo”
Aardvark Therapeutics had previously voluntarily suspended studies of ARD-101—and a related asset called ARD-201—after detecting anomalous echocardiographic readings in healthy volunteers that could indicate reduced heart efficiency.
Original title: “Future of Aardvark’s Prader-Willi drug in doubt as FDA slaps full hold on program”
metabolic profile in prader willi syndrome patients followed at a single expert center of rare endocrine diseases
Original title: “Metabolic profile in Prader-Willi syndrome patients followed at a single expert center of rare endocrine diseases.”
The deal hands Neurocrine a “controversial” medicine, Vykat, that achieved $190 million in sales last year but faces persistent questions about its growth trajectory and safety, according to Wall Street analysts.
Original title: “Neurocrine to acquire Prader-Will drug in $2.9B Soleno buyout”
While an acquisition is a good exit for Soleno Therapeutics, the company’s acceptance of Neurocrine Biosciences’ $53-per-share offer came as a surprise to Stifel analysts given the potential growth of Vykat XR, approved last year for extreme hunger in patients with Prader-Willi syndrome.
Original title: “Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal”
pharmacological management of obesity in prader willi syndrome what does the future hold
Original title: “The pharmacological management of obesity in Prader-Willi syndrome: what does the future hold?”
Aardvark Therapeutics is down 54% since Friday after the biotech said it detected “reversible cardiac observations” in a healthy volunteer study of its drug to treat extreme hunger in patients with the rare genetic disease.
Original title: “Aardvark Tanks After Pausing Prader-Willi Study on ‘Surprise’ Safety Signals”
The detection of certain cardiac issues in a study of healthy volunteers led Aardvark to pause a Phase 3 trial only months before an expected data readout.
Original title: “Safety concerns spur Aardvark to halt key Prader-Willi drug trial”
Aardvark Therapeutics is voluntarily pausing its late-stage trial testing its experimental treatment for a type of rare genetic disease after it found heart-related side effects in healthy volunteers, the company said on Friday. Feb 27 (Reuters) - Aardvark Therapeutics (AARD.O), opens new tab is voluntarily pausing its late-stage trial testing its experimental treatment for a type of rare genetic disease after it found heart-related side effects in healthy volunteers, the company said on Friday. Aardvark was testing ARD-101 as a potential treatment for hyperphagia, or feelings of intense and persistent hunger, in patients with a rare genetic disorder called Prader-Willi syndrome. The company said it is conducting a comprehensive review of the data to inform next steps. "We are committed to advancing the ARD-101 clinical program and we are evaluating optimal therapeutic dosing levels to support its progress," CEO Tien Lee said in a statement. Currently, only one FDA-approved treatment exists for hyperphagia, a once-daily oral pill called Vykat XR by Soleno Therapeutics (SLNO.O), opens new tab. Last year, Acadia Pharmaceuticals (ACAD.O), opens new tab said it will discontinue development of its intranasal therapy to treat Prader-Willi syndrome after it failed to show a benefit in patients in a late-stage trial.
Original title: “Aardvark pauses late-stage trial testing rare disease treatment | Reuters”
understanding the burden of endocrine and metabolic disorders in prader willi syndrome data from the italian registry
Original title: “Understanding the burden of endocrine and metabolic disorders in Prader-Willi syndrome: data from the Italian registry.”
oxytocin in infants with prader willi syndrome to improve dysphagia and disease trajectory
Original title: “Oxytocin in infants with Prader-Willi syndrome to improve dysphagia and disease trajectory.”